NASDAQ:TYRA Tyra Biosciences Q3 2026 Earnings Date & Estimates $20.36 +0.40 (+1.98%) As of 02:24 PM Eastern This is a fair market value price provided by Massive. Learn more. Tyra Biosciences is scheduled to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. The conference call is scheduled for 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 4, 2026TimeBefore Market OpensConference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Tyra Biosciences in Q3 2026Tyra Biosciences is expected to post earnings of -$0.66 per share. In the same quarter a year earlier Tyra Biosciences reported -$0.50 per share. Tyra Biosciences last reported on August 4, 2026, posting -$0.69 per share and missing the -$0.6499 consensus estimate. Tyra Biosciences has beaten the consensus EPS estimate in 3 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.66Prior-Year EPS-$0.50Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.69 (Missed by -$0.0401)EPS Beat Rate3 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Tyra Biosciences Q3 2026 Earnings FAQ When does Tyra Biosciences report Q3 2026 earnings? Tyra Biosciences (NASDAQ:TYRA) is scheduled to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. What time is Tyra Biosciences' Q3 2026 earnings call? Tyra Biosciences' Q3 2026 earnings conference call is scheduled for Wednesday, November 4, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Tyra Biosciences? Analysts expect Tyra Biosciences to post earnings of -$0.66 per share for Q3 2026. Tyra Biosciences Earnings HeadlinesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRAOctober 8 at 10:00 AM | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRAOctober 6 at 4:50 PM | globenewswire.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.October 9 at 1:00 AM | Profits Run (Ad)Raymond James Updates Healthcare Top Picks for OctoberOctober 3, 2026 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRAOctober 1, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRASeptember 29, 2026 | globenewswire.comSee More Tyra Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tyra Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tyra Biosciences and other key companies, straight to your email. Email Address About Tyra BiosciencesTyra Biosciences (NASDAQ:TYRA) is a clinical-stage biotechnology company focused on developing precision medicines for cancers and other diseases driven by genetic alterations. The company uses its proprietary SNAP platform to design small-molecule therapies intended to selectively target clinically important mutations while addressing resistance mechanisms that can limit existing treatments. Tyra’s lead development program is TYRA-300, an orally administered, selective FGFR3 inhibitor being evaluated for the treatment of FGFR3-driven cancers, including urothelial carcinoma. The company is also investigating TYRA-300 in skeletal dysplasia, including achondroplasia, and is developing additional FGFR-targeted programs for oncology indications. Founded in 2018 and headquartered in Carlsbad, California, Tyra Biosciences conducts research and clinical development activities through its operations in the United States. The company was co-founded by Todd Harris, who serves as chief executive officer and is involved in guiding its drug-discovery and development strategy.View Tyra Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueMicrosoft Is Almost Back to $555—Now the Hard Part BeginsSkydance Just Became a Media Giant—With an $80 Billion Debt Load Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
